Dowdy, D. (2021, September 21). On the J&J booster news, keep in mind: 1. Median follow-up since 2nd dose was just 36 days, 2. Efficacy vs moderate COVID was 75% globally, and 3. Total number of cases in the US was 15. Please don’t take this to mean that a 2nd dose provides long-term increase in protection. Https://t.co/RnqDNBmwuD [Tweet]. @davidwdowdy. https://twitter.com/davidwdowdy/status/1440323242942554122

Eran Segal. (2021, August 17). Israel data showing the decay of vaccine efficacy over time. Y-axis is cases per 1000 from July 7 to Aug 10, for unvaccinated, and for people vaccinated at different times Cases are higher in those vaxed earlier Despite world-data caveats, this seems quite compelling https://t.co/5aNz48AC8F [Tweet]. @segal_eran. https://twitter.com/segal_eran/status/1427696623988117505

Clover’s COVID-19 Vaccine Candidate Demonstrates 79% Efficacy Against Delta in Global Phase 2/3 SPECTRA Trial Dominated by Variants of Concern and Interest—Clover Biopharmaceuticals. (n.d.). Retrieved 4 October 2021, from https://www.cloverbiopharma.com/news/83.html

Moderna’s COVID-19 Vaccine Still 93% Effective After 6 Months. (n.d.). Time. Retrieved 7 August 2021, from https://time.com/6087722/moderna-vaccine-long-term-efficacy/

Shapiro, J., Dean, N. E., Madewell, Z. J., Yang, Y., Halloran, M. E., & Longini, I. (2021). Efficacy Estimates for Various COVID-19 Vaccines: What we Know from the Literature and Reports [Preprint]. Epidemiology. https://doi.org/10.1101/2021.05.20.21257461

Timing of COVID-19 Vaccine Approval and Endorsement by Public Figures. (2020). https://doi.org/10.21203/rs.3.rs-95823/v1

Moderna Provides Clinical and Supply Updates on COVID-19 Vaccine Program Ahead of 2nd Annual Vaccines Day. (2021, April 13). Moderna, Inc. https://investors.modernatx.com/news-releases/news-release-details/moderna-provides-clinical-and-supply-updates-covid-19-vaccine

Gangarosa, E. J., Galazka, A. M., Wolfe, C. R., Phillips, L. M., Miller, E., Chen, R. T., & Gangarosa, R. E. (1998). Impact of anti-vaccine movements on pertussis control: The untold story. The Lancet, 351(9099), 356–361. https://doi.org/10.1016/S0140-6736(97)04334-1